SARAH BRAMON: Open Payments
NPI 1801203708 · GREENVILLE, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,567 in 79 payments from 18 companies in 2025. Trend: 2023 $1,214 · 2024 $968 · 2025 $1,567
Food & beverage: $1,536Education: $31
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 7 | $272 |
| ABBVIE INC. | 13 | $219 |
| QOL Medical, LLC | 7 | $210 |
| Janssen Biotech, Inc. | 18 | $171 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $138 |
| Madrigal Pharmaceuticals | 5 | $92 |
| Gilead Sciences, Inc. | 4 | $79 |
| Ipsen Biopharmaceuticals, Inc | 3 | $74 |
| PFIZER INC. | 2 | $45 |
| Boston Scientific Corporation | 1 | $43 |
Products named: DUPIXENT, Sucraid, TREMFYA, ENTYVIO, REZDIFFRA, CREON, IQIRVO, LINZESS.
Industry payments across SC — which companies pay providers there.
